Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 6
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
CLDN18.2 expression
pancreatic cancer · Combination Therapy
CLDN18.2 expression is flagged as trial selection rising because public trials show inclusion required evidence in 8 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07415525 | https://clinicaltrials.gov/study/NCT07444541 | https://clinicaltrials.gov/study/NCT07079228 | https://clinicaltrials.gov/study/NCT06396091 | https://clinicaltrials.gov/study/NCT07692750 | https://clinicaltrials.gov/study/NCT07108504 | https://clinicaltrials.gov/study/NCT03816163 | https://clinicaltrials.gov/study/NCT07597772